Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR | Market Cap | 1.08B +256.9% |
| Revenue (ttm) | 787.71M +74.1% |
| Net Income | 10.55M +213.8% |
| EPS | 0.95 +182.6% |
| Shares Out | 13.18M |
| PE Ratio | 85.93 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,683 |
| Open | 82.67 |
| Previous Close | 77.98 |
| Day's Range | 80.10 - 84.50 |
| 52-Week Range | 29.00 - 92.52 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 27, 2026 |
About Concord Drugs
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. The company was incorporated in 1995 and is based in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, Concord Drugs's revenue was 787.71 million, an increase of 74.10% compared to the previous year's 452.45 million. Earnings were 10.55 million, an increase of 213.80%.
Financial StatementsNews
Concord Drugs Q3FY25 Results: Revenue declines 15.53% YoY to Rs 10.79 crore
Concord Drugs has announced its unaudited financial results for the third quarter ended December 31, 2024. The company reported mixed performance metrics, reflecting challenges in its operations for t...